What are the most effective real-time markers of kidney cell damage?

NGAL, [TIMP‑2]·[IGFBP7], and KIM-1 are the most effective real-time markers of kidney cell damage, showing high diagnostic accuracy when measured at appropriate time windows and achieving superior performance when combined in multi-marker panels.

Abstract

Real‐time markers for kidney cell damage most consistently report high diagnostic accuracy when measured in the appropriate clinical context and time window. Urinary neutrophil gelatinase‐associated lipocalin (NGAL) rises within 2–6 hours after injury, with studies reporting area under the curve (AUC) values up to 0.91, sensitivities of 84–100%, and specificities as high as 99.5%. Urinary [TIMP‑2]·[IGFBP7] is typically measured at 6–12 hours post‐injury and shows AUC values ranging from 0.70 to 0.94, with reported sensitivities of 42–96% and specificities up to 95%. Urinary kidney injury molecule‑1 (KIM‑1) measured at 12–24 hours post‐insult yields moderate performance (AUC 0.66–0.84) with sensitivities between 75.9% and 91.6% and specificities up to 95.2%.

When combined in multi‐marker panels, these biomarkers often achieve superior performance. For example, panels including NGAL, [TIMP‑2]·[IGFBP7], and cystatin C have produced AUC values as high as 0.98, supporting their use as effective real‐time indicators of kidney cell damage.

Methods

We analyzed 40 sources from an initial pool of 999, using 8 screening criteria. Each paper was reviewed for 5 key aspects that mattered most to the research question.

Screening Criteria

• Real-time Biomarker Detection: Evaluates biomarkers that can detect kidney cell damage in real-time (within 24 hours).
• Human Participants: Involves human participants with actual or potential kidney cell damage.
• Diagnostic Performance: Assesses diagnostic performance metrics (sensitivity, specificity, AUC, etc.).
• Study Design: Includes prospective cohort studies, cross-sectional diagnostic accuracy studies, etc.
• Comparative Assessment: Compares novel biomarkers with established reference standards.
• Clinical Study Setting: Conducted in a clinical setting.
• Primary Research Quality: Involves primary or high-quality secondary research.
• Clinical Utility Assessment: Assesses the diagnostic performance or clinical utility of biomarkers.

Data Collection

Individual Biomarker Performance

Combined Biomarker Performance

Several studies reported that combinations of biomarkers outperformed individual markers. For instance:

• A combination of NGAL, IL-18, and [TIMP-2] yielded an AUC of 0.973 at 12 hours post-cardiopulmonary bypass.
• The combination of [TIMP-2]·[IGFBP7] and clinical factors improved predictive accuracy significantly.

Timing of Detection and Clinical Context

Discussion

The effectiveness of real-time kidney cell damage markers is influenced by clinical context, timing, comorbidities, and methodological factors. Standardization of definitions and analytical methods is needed to optimize and compare biomarker performance across studies.